AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.

By P. Jänne, Jie Yang, Dong-Wan Kim, D. Planchard, Yuichiro Ohe, S. Ramalingam, M. Ahn, Sang-We Kim, W. Su, L. Horn and 9 more. New England Journal of Medicine, 2015

1,903 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/f9314c8da8733e870b830f3af40dae87a2f7eaa2

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. J. Baselga
2. Nikolaus Schultz
3. Jie Yang
4. Gregory Riely
5. M. Hellmann
6. M. Callahan
7. P. Jänne
8. M. Postow

In Pulmonary and Respiratory Medicine

1. P. Jänne
2. J. Baselga
3. Marc Ladanyi
4. Gregory Riely
5. Jin-Yuan Shih
6. Shang-Gin Wu
7. William Pao

Citations in the corpus

• Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer (2018, neutral): “Based on efficacy and safety, 80 mg daily was selected as the recommended dose for further clinical trials [92].”
• Overcoming EGFR T790M and C797S resistance with mutant-selective allosteric inhibitors (2016, positive): “Compounds of this class are demonstrating significant efficacy against T790M mutant tumors in ongoing clinical trials 17,18 , and osimertinib was recently approved by the U.S. Food and Drug Administration for patients with EGFR T790M-positive NSCLC following progression on prior EGFR TKI therapy.”
• OncoKB: A Precision Oncology Knowledge Base (2017, background): “…for erlotinib, gefitinib and afatinib, but is also classified as Level 1, as it predicts sensitivity to the EGFR inhibitor osimertinib, which was recently approved for use in patients with NSCLC that have progressed on first-line EGFR TKI therapy and whose tumors harbor the EGFR T790M mutation 44 .”
• Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. (2016, background): “There are now three trials on osimertinib (AZD9291).(13,22,23) The most recent publication at the time of this guideline’s development was a phase III RCT comparing osimertinib with pemetrexed plus a platinum agent.”
• Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology (2018, background): “Finally, it should be noted that trials are currently underway to assess the value of these third-generation EGFR inhibitors as first-line treatment of EGFR-mutant lung adenocarcinoma.(220,221,236) Data are emerging(237) that a second acquired resistance mutation, C797S, can arise in tumors that hav”
• Rociletinib in EGFR-mutated non-small-cell lung cancer. (2015, neutral): “Muscle spasms 13 (10) 3 (8) 4 (21) 3 (18) 0 3 (9) 0 10 (11)”